drugset / Trial / NCT01803711

Omega 3 FA Supplements as Augmentation in the Treatment of Depression

NCT01803711

Phase 2/3 Terminated 6 enrolled UConn Health
RandomizedParallel-groupTriple-blindTreatment

Summary

To assess the efficacy of Omega 3 Fatty acid (Omega 3 FA) augmentation of desvenlafaxine (DVS) compared to placebo augmentation of DVS when used to treat depression and anxiety symptoms in patients with select medical conditions (cancer, cardiovascular diseases and diabetes).

Timeline

Start
2013-02
Primary completion
2016-06
Completion
2016-06

Drugs

EvaluationDrugModalityDoseRoute
Background Desvenlafaxine Other / unclassified 50 mg